Retatrutide appears to be a new pharmaceutical in the fight against obesity. This groundbreaking drug, categorized as a dual GLP-1 and GIP receptor agonist, exhibits promising results in investigations. By boosting these receptors, Retatrutide controls cravings, {promotesglucose regulation, and ultimately contributes to significant reduction in bod